Examination of Cardiovascular Function/ Cardio Respiratory Interaction on Spontaneous Breathing Trials in Patients in the Prolonged Weaning (Weaning TTE)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Michael Dreher, MD
- Phone Number: +49 241 80 88763
- Email: mdreher@ukaachen.de
Study Locations
-
-
-
Aachen, 52074, Germany
- Recruiting
- University Hospital RWTH Aachen, Department of Medical Clinic I
-
Principal Investigator:
- Michael Dreher, MD
-
Sub-Investigator:
- Johannes Bickenbach, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- legal Age (≥18 years)
- written informed consent Prior to study participation
patient in prolonged weaning with NYHA I-II and an actual positive Ventilator Screening test:
- PaO2 ≥ 60 mmHg at FiO2 ≤ 0.4
- PEEP ≤ 8 cmH2O
- Glasgow Coma Scale > 13
- Temp. < 38°C
- Hb > 80-100 g/L
- less requirement on catecholamines (<0.1µg/kg/min)
and on these patients are already performed a spontaneous breathing trial with following result:
- abortion this spontaneous breathing trial < 30min, but possible > 10min
- reason for an abortion was NOT hypercapnia
Exclusion Criteria:
- weaning patients are assigned on Group 1-2
- patient with heart failure (NYHA III-IV) and/ or other cardiac comorbidity
- acute NSTEMI (non-ST-segment elevation myocardial infarction)
- pregnancy and breast-feeding
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
spontaneous breathing trials
spontaneous breathing trials in patients with prolonged weaning
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Baseline measurement (Modus "CPAP-PS") in patient with prolonged weaning
Time Frame: 12 months
|
under pressure support Ventilation are determined some measurement (e.g.
breathing rate)
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intervention measurement in patient with prolonged weaning
Time Frame: 12 months
|
20 min breathing without mechanical ventilation
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Michael Dreher, MD, Uniklinik RWTH Aachen, Med. Klinik I
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CTC-A 15-034
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Disease
-
NCT02729389CompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular Disease
-
NCT07187947RecruitingCardiovascular Disease (CVD) | Gender Incongruence | Cardiovascular (CV) Risk | Cardiovascular Health Status | Cardiovascular Disease Prevention | Cardiovascular Disease Acute | Cardiovascular Disease Risk Factor
-
NCT02122575CompletedCardiovascular Disease | Inflammatory Disease
-
NCT07401550RecruitingCoronary Artery Disease (CAD) | Cardiovascular Diseases (CVD) | Cardiovascular Disease Prevention | Cardiovascular Disease Risk Factor
-
NCT07497932RecruitingCardiovascular Disease | Cardiovascular Surgery
-
NCT07466056Recruiting
-
NCT02508454Active, not recruitingCardiovascular Disease
-
NCT01343342Active, not recruitingCardiovascular Disease
-
NCT00439582CompletedCardiovascular Disease
-
NCT00685581Completed
Clinical Trials on Spontaneous breathing trial
-
NCT06923267RecruitingSpontaneous Breathing Test | Intensive Care Units (ICUs) | Weaning-induced Pulmonary Edema | Weaning Failure of Mechanical Ventilation | Weaning Invasive Mechanical Ventilation
-
NCT05226247RecruitingMechanical Ventilation Complication | Pulmonary Edema
-
NCT01471431TerminatedRespiratory Distress Syndrome
-
NCT06391424RecruitingCritical Illness | Oxygen Consumption | Intensive Care Unit | Weaning Failure | Mechanical Ventilation | Spontaneous Breathing Trial
-
NCT05318261CompletedWeaning Failure | Spontaneous Breathing Trial | Weaning-induced Pulmonary Edema
-
NCT07564258Not yet recruitingAcute Respiratory Disease
-
NCT03956511CompletedInfant, Newborn, Diseases | Airway Morbidity
-
NCT01616901CompletedObesity | Respiratory Failure | PSV 7cmH2O PEEP 7cmH2O | PSV 7 cmH2O PEEP 0 cmH20 | CPAP 7 cmH2O | PSV 0 cmH20 PEEP 0 cmH2O | T-Tube | Post-extubation in Spontaneous Breathing and/or in NIV
-
NCT01020773CompletedRespiratory Failure